Assessing Prevalence Of Beta Lactamase Production From Clinical Isolates Of Hospitalized Patients And Comparison Of Antibiotic Susceptibility Patterns
NCT ID: NCT00728624
Last Updated: 2017-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2039 participants
OBSERVATIONAL
2008-11-30
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objectives:
* Comparison of antimicrobial susceptibility using disc-diffusion method
* Assessing prevalence of beta-lactamase producing strains among clinical isolates obtained from hospital in-patients
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Evaluation of Beta-Lacta ™ Test in Urinary Infections
NCT02897609
The Prevalence of Extend-Spectrum β-Lactamase (ESBL) Producing Isolates Among Common Enterobacteriaceae in Taiwan
NCT01725841
Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms
NCT00573521
Community - Associated Extended-spectrum Beta-lactamases (ESBL)
NCT00363220
Prevalence of Enterobacteria With Decreased Susceptibility to Carbapenems in Eastern Inter- Region
NCT02803710
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
Isolates identified as commensals or contaminants will be excluded
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Hyderabad, Andhra Pradesh, India
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Manipal, Karnataka, India
Pfizer Investigational Site
Mumbai, Maharashtra, India
Pfizer Investigational Site
Chandigarh, Punjab, India
Pfizer Investigational Site
Porur, Chennai, Tamil Nadu, India
Pfizer Investigational Site
Kolkata, West Bengal, India
Pfizer Investigational Site
Kolkata, West Bengal, India
Pfizer Investigational Site
Kolkata, West Bengal, India
Pfizer Investigational Site
Chennai, , India
Pfizer Investigational Site
New Delhi, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A1891005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.